Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045638 | 0.89 | KMT2A (0.79) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5501524 | 0.88 | KMT2A (0.74) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5506586 | 0.87 | KMT2A (0.76) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5501450 | 0.87 | KMT2A (0.76) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5505918 | 0.86 | KMT2A (0.77) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL530155 | 0.84 | KMT2A (0.78) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5505490 | 0.82 | KMT2A (0.65) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5315591 | 0.81 | KMT2A (0.77) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL5981802 | 0.81 | MEN1 (0.50) | KMT2AMEN1PKMMAPTNPSR1 | |
| SCHEMBL9175601 | 0.80 | MEN1 (0.74) | KMT2AMEN1PKMMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753724-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | SIRCAR JAGADISH C | 2006-01-12 | — | — | US | disclosed |
| WO-2005123686-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | LDLR, NPC1L1, CETP | KMT2A 3106/4885MEN1 4136/4885PKM 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.